• Je něco špatně v tomto záznamu ?

miR-139-5p controls translation in myeloid leukemia through EIF4G2

S. Emmrich, F. Engeland, M. El-Khatib, K. Henke, A. Obulkasim, J. Schöning, JE. Katsman-Kuipers, C. Michel Zwaan, A. Pich, J. Stary, A. Baruchel, V. de Haas, D. Reinhardt, M. Fornerod, MM. van den Heuvel-Eibrink, JH. Klusmann,

. 2016 ; 35 (14) : 1822-31. [pub] 20150713

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16028372
E-zdroje Online Plný text

NLK ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 26165837
DOI 10.1038/onc.2015.247
Knihovny.cz E-zdroje

MicroRNAs (miRNAs) are crucial components of homeostatic and developmental gene regulation. In turn, dysregulation of miRNA expression is a common feature of different types of cancer, which can be harnessed therapeutically. Here we identify miR-139-5p suppression across several cytogenetically defined acute myeloid leukemia (AML) subgroups. The promoter of mir-139 was transcriptionally silenced and could be reactivated by histone deacetylase inhibitors in a dose-dependent manner. Restoration of mir-139 expression in cell lines representing the major AML subgroups (t[8;21], inv[16], mixed lineage leukemia-rearranged and complex karyotype AML) caused cell cycle arrest and apoptosis in vitro and in xenograft mouse models in vivo. During normal hematopoiesis, mir-139 is exclusively expressed in terminally differentiated neutrophils and macrophages. Ectopic expression of mir-139 repressed proliferation of normal CD34(+)-hematopoietic stem and progenitor cells and perturbed myelomonocytic in vitro differentiation. Mechanistically, mir-139 exerts its effects by repressing the translation initiation factor EIF4G2, thereby reducing overall protein synthesis while specifically inducing the translation of cell cycle inhibitor p27(Kip1). Knockdown of EIF4G2 recapitulated the effects of mir-139, whereas restoring EIF4G2 expression rescued the mir-139 phenotype. Moreover, elevated miR-139-5p expression is associated with a favorable outcome in a cohort of 165 pediatric patients with AML. Thus, mir-139 acts as a global tumor suppressor-miR in AML by controlling protein translation. As AML cells are dependent on high protein synthesis rates controlling the expression of mir-139 constitutes a novel path for the treatment of AML.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16028372
003      
CZ-PrNML
005      
20161027114403.0
007      
ta
008      
161005s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/onc.2015.247 $2 doi
024    7_
$a 10.1038/onc.2015.247 $2 doi
035    __
$a (PubMed)26165837
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Emmrich, S $u Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
245    10
$a miR-139-5p controls translation in myeloid leukemia through EIF4G2 / $c S. Emmrich, F. Engeland, M. El-Khatib, K. Henke, A. Obulkasim, J. Schöning, JE. Katsman-Kuipers, C. Michel Zwaan, A. Pich, J. Stary, A. Baruchel, V. de Haas, D. Reinhardt, M. Fornerod, MM. van den Heuvel-Eibrink, JH. Klusmann,
520    9_
$a MicroRNAs (miRNAs) are crucial components of homeostatic and developmental gene regulation. In turn, dysregulation of miRNA expression is a common feature of different types of cancer, which can be harnessed therapeutically. Here we identify miR-139-5p suppression across several cytogenetically defined acute myeloid leukemia (AML) subgroups. The promoter of mir-139 was transcriptionally silenced and could be reactivated by histone deacetylase inhibitors in a dose-dependent manner. Restoration of mir-139 expression in cell lines representing the major AML subgroups (t[8;21], inv[16], mixed lineage leukemia-rearranged and complex karyotype AML) caused cell cycle arrest and apoptosis in vitro and in xenograft mouse models in vivo. During normal hematopoiesis, mir-139 is exclusively expressed in terminally differentiated neutrophils and macrophages. Ectopic expression of mir-139 repressed proliferation of normal CD34(+)-hematopoietic stem and progenitor cells and perturbed myelomonocytic in vitro differentiation. Mechanistically, mir-139 exerts its effects by repressing the translation initiation factor EIF4G2, thereby reducing overall protein synthesis while specifically inducing the translation of cell cycle inhibitor p27(Kip1). Knockdown of EIF4G2 recapitulated the effects of mir-139, whereas restoring EIF4G2 expression rescued the mir-139 phenotype. Moreover, elevated miR-139-5p expression is associated with a favorable outcome in a cohort of 165 pediatric patients with AML. Thus, mir-139 acts as a global tumor suppressor-miR in AML by controlling protein translation. As AML cells are dependent on high protein synthesis rates controlling the expression of mir-139 constitutes a novel path for the treatment of AML.
650    _2
$a zvířata $7 D000818
650    _2
$a buněčná diferenciace $x genetika $7 D002454
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x genetika $7 D049109
650    _2
$a eukaryotický iniciační faktor 4G $x biosyntéza $x genetika $7 D039603
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u leukemie $7 D015973
650    _2
$a genový knockdown $7 D055785
650    _2
$a lidé $7 D006801
650    _2
$a myeloidní leukemie $x genetika $x patologie $7 D007951
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a mikro RNA $x biosyntéza $x genetika $7 D035683
650    12
$a proteosyntéza $7 D014176
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Engeland, F $u Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
700    1_
$a El-Khatib, M $u Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
700    1_
$a Henke, K $u Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
700    1_
$a Obulkasim, A $u Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands.
700    1_
$a Schöning, J $u Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
700    1_
$a Katsman-Kuipers, J E $u Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands.
700    1_
$a Michel Zwaan, C $u Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands.
700    1_
$a Pich, A $u Institute for Toxicology, Hannover Medical School, Hannover, Germany.
700    1_
$a Stary, J $u Department of Pediatric Hematology/Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Baruchel, A $u Department of Hematology, Hopitaux universitaires Saint-Louis, St Louis Hospital, Paris, France.
700    1_
$a de Haas, V $u Dutch Childhood Oncology Group (DCOG), Stichting Kinderoncologie Nederland (SKION), Hague, The Netherlands.
700    1_
$a Reinhardt, D $u Clinic for Pediatrics III, University Hospital Essen, Essen, Germany.
700    1_
$a Fornerod, M $u Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands. Department of Biochemistry, Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands.
700    1_
$a van den Heuvel-Eibrink, M M $u Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands.
700    1_
$a Klusmann, J H $u Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
773    0_
$w MED00003600 $t Oncogene $x 1476-5594 $g Roč. 35, č. 14 (2016), s. 1822-31
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26165837 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161027114820 $b ABA008
999    __
$a ok $b bmc $g 1166686 $s 953002
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 35 $c 14 $d 1822-31 $e 20150713 $i 1476-5594 $m Oncogene $n Oncogene $x MED00003600
LZP    __
$a Pubmed-20161005

Najít záznam

Citační ukazatele

Možnosti archivace